Solution Sales Executive, BenevolentAI
Knowledge Exploration
AI-drug discovery
Job no longer available
AI-drug discovery
201-500 employees
Job no longer available
201-500 employees
Company mission
BenevolentAI's mission is to unlock the power of AI to transform drug discovery and bring effective medicines to every patient. Their vision is to drive transformational change through scalable technology solutions that result in a consistent pipeline of successful trials and new medicines for patients.
Role
Who you are
- The ideal candidate is a strategic thinker, a persuasive communicator, and possesses a deep understanding of the challenges and opportunities in biopharma drug development
- Education: Bachelor's degree in a relevant field; advanced degree (MBA, MSc) is a plus
- Experience: A minimum of 5 years of experience in solution sales, selling technology to the pharmaceutical and biotech sectors. Proven track record of meeting or exceeding sales targets
- Industry Knowledge: Strong understanding of the pharmaceutical and biotech industries, with knowledge of drug discovery and development processes and challenges
- Communication Skills: Exceptional verbal and written communication skills. Ability to articulate complex concepts in a clear and concise manner
- Sales Acumen: Strong sales instincts, with the ability to identify and pursue opportunities strategically. Adept at consultative selling and building long-term client relationships
- Results-Oriented: Demonstrated ability to drive results in a fast-paced and dynamic environment. A self-starter with a proactive and goal-oriented mindset
- Team Player: Collaborative and able to work effectively in a team-oriented environment. Willingness to contribute ideas and collaborate with cross-functional teams
What the job involves
- We are seeking a highly motivated and results-driven Solution Sales Executive to join our dynamic sales team
- In this role, you will be responsible for driving the sales of our SaaS Knowledge Exploration Suite of tools to biopharma companies globally
- Solution Sales: Lead the end-to-end sales process, from prospecting to closing deals, by effectively positioning and selling BenevolentAI's SaaS Knowledge Exploration Suite of tools to pharmaceutical and biotech companies. Work closely with internal product, scientific, and commercial teams across the sales cycle
- Client Engagement: Develop and nurture strong relationships with key decision-makers, understanding their business needs and challenges. Collaborate with clients to tailor solutions that address their specific requirements
- Negotiation and Closure: Lead contract negotiations, addressing client concerns, and ensuring mutually beneficial terms. Drive the sales process to successful closures while meeting or exceeding revenue targets
- Market Expertise: Stay abreast of industry trends, market dynamics, and competitive landscapes within the biopharma drug development solutions market. Leverage this knowledge to position BenevolentAI's solutions as a strategic advantage for clients
- Product Knowledge: Develop a deep understanding of BenevolentAI's products and solutions. Effectively communicate the value proposition, features, and benefits to potential clients through compelling presentations and demonstrations
- Sales Strategy: Work closely with the sales and marketing team and leadership to develop and execute sales strategies that align with overall business objectives. Identify new business opportunities and contribute to the development of sales collateral
- Opportunity Management: Build and manage a robust pipeline of opportunities, consistently evaluating and prioritising opportunities based on strategic fit and potential impact on business objectives
- Cross-Functional Collaboration: Collaborate with internal teams, including product development, marketing, and customer success, to ensure a seamless client experience and contribute to ongoing product enhancements based on client feedback
Otta's take
Xav Kearney
CTO of Otta
There is a lot of research being done in the pharmaceutical industry. BenevolentAI say there's a new research paper being published every 30 seconds. They argue this information is not being used in a smart way for the discovery and development of new drugs.
To tackle this problem, BenevolentAI uses artificial intelligence to analyse biomedical information, from clinical trials data to academic papers. They can then identify molecules that have failed in clinical trials and predict how these same compounds can instead be more efficient targeting other diseases.
They argue this approach can dramatically accelerate the discovery of new drugs. They've collaborated with large pharma companies like AstraZeneca and Johnson & Johnson subsidiary Janssen Pharmaceutica. A SPAC merger of 1.5 billion euros included AstraZeneca as an investor and will help BenevolentAI accelerate product development.
It's a big market, with Global Market Insights estimating the global healthcare AI market will exceed $10 billion by 2024. This gives them a big opportunity, but it won't be an easy problem to tackle.
Insights
Some candidates hear
back within 2 weeks
51% female employees
15% employee growth in 12 months
Company
Funding (last 2 of 3 rounds)
Sep 2019
$90m
LATE VC
Apr 2018
$115m
LATE VC
Total funding: $305m
Company benefits
- Work from home opportunities
Company values
- Put patients first: Everything we do is geared to getting the right medicine to the right patient, faster
- Break boundaries: We deliberately cross traditional boundaries between technology and science, human and machine, to create unique approaches
- Own the solution: We never hold back from contributing our point of view and taking responsibility
- Drive to delivery: We use data to drive decision-making and deliver with the right level of validation
Company HQ
Fitzrovia, London, UK
Founders
Joanna Shields
(CEO, not founder)Long career in technology, having previously worked at Google, Facebook and Bebo. Appointed to the House of Lords in 2014 and works as a Digital Economy Adviser to the UK Government.
Michael Brennan
(Co-founder & Non-Executive Director)Previously Head of Corporate Development at BenevolentAI. Before cofounding the company, they were Head of Corporate Development at Proximagen Group and Chief Executive of Novum Securities.
Ivan Griffin
(Co-founder & COO)Worked as a Venture Capitalist for over a decade. Also helped launch Genomics England Ltd, a Company created to deliver the 100,000 Genomes Project as launched by the Prime Minister in 2013. Holds a D.Phil. in Cognitive Neuroscience from the University of Oxford where they also completed a year’s post-doctoral research.
People progressing
Joined as a Biomedical Informatics Manager. Promoted to VP after 10 months, then again to SVP of Informatics and Data.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 3 more jobs at BenevolentAI